Shots:

• Renovacor shareholders to receive ~0.1676 shares of Rocket in exchange for each of their shares in Renovaco & are expected to own ~4.6% of Rocket with a total equity deal value of ~$53M, $2.60/share of Renovacor based on the volume weighted avg. the trading price of Rocket shares of $15.51 for the 30 trading days. The transaction is expected to close in Q1’23
• The acquisition strengthens Rocket’s leadership in AAV-based cardiac gene therapy & expands clinical assets for heart conditions
• The acquisition will combine Renovacor’s preclinical work with Rocket’s joint clinical, regulatory & CMC expertise to advance gene therapy. Renovacor’s REN-001 is an AAV-based gene therapy targeting BAG3-associated DCM

Ref: Businesswire | Image: Renovacor